The Oncogenic Palmitoyi-Protein Network in Prostate Cancer
Technical Report,01 Mar 2010,31 Mar 2015
Cedars-Sinai Medical Center Los Angeles United States
Pagination or Media Count:
Epidemiologica l data indicate that cholesterol-lowering pharmacotherapy, primarily HGM-CoA-reductase inhibitors status, reduce the risk of aggressive prostate cancer PCa. The FDA-approved anti obesity drug, Ortistat, which inhibits the enzyme fatty acid synthase FASN, has been shown to slow the growth of human prostate tumors in mice. Despite these advances, studies of lipid metabolism in PCa have lagged behind other areas of research on cell signaling, and limited information is available about how these promising preclinical and clinical data might be leveraged to improve patient outcomes. Our hypothesis is that PCa progression is dependent on a palmitoyl-protein network regulated by FASN. We predict that the activity of this network can be suppressed by reducing levels of circulating cholesterol. Specific Aims We will challenge this hypothesis with the following specific A Identify critical palmitoyl-proteins in the FASN subnetwork.